{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Experiences Revision in Stock Evaluation Amid Market Challenges
Iovance Biotherapeutics, Inc. has experienced a stock price decline, currently at $2.21, with a notable 52-week range. Technical indicators show mixed performance, reflecting varied momentum. The company has struggled significantly over the past year, contrasting sharply with the S&P 500's gains, highlighting ongoing market challenges.
Is Iovance Biotherapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Iovance Biotherapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a year-to-date return of -70.14%.
Is Iovance Biotherapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Iovance Biotherapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 by -68.38% year-to-date.
Is Iovance Biotherapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Iovance Biotherapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, having returned 10.90% over the past week and 5.88% over the past month, but a year-to-date return of -68.38% compared to the S&P 500's 14.18%.
Iovance Biotherapeutics Experiences Revision in Stock Evaluation Amid Market Volatility
Iovance Biotherapeutics, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock price is currently $2.12, reflecting notable volatility over the past year. Technical indicators present mixed signals, and the company's performance has significantly lagged behind the S&P 500, underscoring ongoing challenges.
Is Iovance Biotherapeutics, Inc. technically bullish or bearish?
As of September 19, 2025, Iovance Biotherapeutics, Inc. is in a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with a year-to-date return of -71.35%.
Is Iovance Biotherapeutics, Inc. technically bullish or bearish?
As of September 19, 2025, Iovance Biotherapeutics, Inc. has a bearish technical trend, underperforming the S&P 500 with a year-to-date return of -72.30% compared to the index's 13.31%.
Is Iovance Biotherapeutics, Inc. technically bullish or bearish?
As of September 5, 2025, Iovance Biotherapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, significantly underperforming the S&P 500 with a year-to-date return of -70.27%.
Is Iovance Biotherapeutics, Inc. overvalued or undervalued?
As of February 28, 2024, Iovance Biotherapeutics, Inc. is considered risky due to overvaluation indicated by a Price to Book Value of 0.89, an EV to Sales ratio of 1.57, a troubling ROCE of -95.61%, and a year-to-date stock performance of -70.27%, significantly underperforming the S&P 500's 12.22% return.
Is Iovance Biotherapeutics, Inc. overvalued or undervalued?
As of February 28, 2024, Iovance Biotherapeutics, Inc. is considered risky and overvalued, with a Price to Book Value of 0.89, an EV to Sales ratio of 1.57, a ROCE of -95.61%, and a year-to-date stock performance decline of 75%, significantly underperforming compared to its peers and the S&P 500.
Is Iovance Biotherapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, Iovance Biotherapeutics, Inc. exhibits a bearish technical trend with moderate strength, supported by bearish indicators across daily moving averages, Bollinger Bands, and KST, despite a mildly bullish weekly MACD signal.
Who are in the management team of Iovance Biotherapeutics, Inc.?
As of March 2022, the management team of Iovance Biotherapeutics, Inc. includes Dr. Iain Dukes (Chairman), Dr. Maria Fardis (CEO), Dr. Athena Countouriotis, Mr. Ryan Maynard, Gen. (Retd.) Merrill McPeak, Mr. Wayne Rothbaum, and Dr. Michael Weiser as independent directors. They oversee the company's strategic direction and operations.
What does Iovance Biotherapeutics, Inc. do?
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer immunotherapy. As of March 2025, it has a market cap of $674.55 million, with net sales of $49 million and a net loss of $116 million.
How big is Iovance Biotherapeutics, Inc.?
As of Jun 18, Iovance Biotherapeutics, Inc. has a market capitalization of 674.55 million, with net sales of 212.67 million and a net profit of -375.36 million over the latest four quarters. The company reported shareholder's funds of 710.40 million and total assets of 910.43 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
